<DOC>
	<DOCNO>NCT00600756</DOCNO>
	<brief_summary>The trial design assess long term subjective well-being schizophrenic outpatient treat quetiapine XR ( extended release ) oral risperidone flexible dose naturalistic setting period one year . Secondary outcome measure select help differentiation compare atypical antipsychotic . The primary objective study demonstrate non-inferiority quetiapine XR risperidone assess month 6 term responder rate use self-report instrument SWN-K</brief_summary>
	<brief_title>Comparison Subjective Well-being Tolerability Quetiapine XR Risperidone</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Treated symptomatic schizophrenia ( DSMIVTR code : 295.10 , 295.20 , 295.30,295.60 , 295.90 ) schizoaffective disorder ( DSMIVTR code:295.70 ) schizophreniform disorder ( DSMIVTR code : 295.40 ) . Patients comorbid depressive symptom may enrol Patient first episode mention disease ( item 3 ) patient require medication change clinical reason ( effectiveness , tolerability , compliance , patient preference ) , i.e . switch typical atypical neuroleptic , switch atypical neuroleptic , exclude patient treat risperidone quetiapine time enrolment . Patients baseline SWNK total score &gt; 75 Patients previous treatment risperidone quetiapine may enrol change treatment dictate major lack tolerability efficacy date last dose least 3 month prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>SWNK</keyword>
</DOC>